Abstract: Certain aspects of the present disclosure provide techniques for reporting an indication of a PHR when the UE's assigned of UL resources is insufficient to transmit both UL data and a PHR. Additionally, aspects described herein introduce a negative PHR used to indicate the UE requires additional UL resources.

Abstract: The various implementations described herein include a percutaneous port for promoting tissue in-growth around the percutaneous port. In one aspect, the percutaneous port includes a tubular structure having an outer surface, and a coil having an outer surface and comprised of a plurality of loops. Furthermore, at least a portion of the outer surface of the coil is joined to the outer surface of the tubular structure.

Abstract: The various implementations described herein include a percutaneous port for promoting tissue in-growth around the percutaneous port. In one aspect, the percutaneous port includes a tubular structure having an outer surface, and a coil having an outer surface and comprised of a plurality of loops. Furthermore, at least a portion of the outer surface of the coil is joined to the outer surface of the tubular structure.

Abstract: The various implementations described herein include a percutaneous port for promoting tissue in-growth around the percutaneous port. In one aspect, the percutaneous port includes a tubular structure having an outer surface, and a coil having an outer surface and comprised of a plurality of loops. Furthermore, at least a portion of the outer surface of the coil is joined to the outer surface of the tubular structure.

Abstract: The various implementations described herein include methods used to manufacture a percutaneous port for promoting tissue in-growth around the percutaneous port. In one aspect, the method includes providing a tubular structure having an outer surface and providing a coil having an outer surface and comprised of a plurality of loops. The method further includes joining at least a portion of the outer surface of the coil to the outer surface of the tubular structure.

Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.

Abstract: The various implementations described herein include methods used to manufacture a percutaneous port for promoting tissue in-growth around the percutaneous port. In one aspect, the method includes providing a tubular structure having an outer surface and providing a coil having an outer surface and comprised of a plurality of loops. The method further includes joining at least a portion of the outer surface of the coil to the outer surface of the tubular structure.

Abstract: The various implementations described herein include a percutaneous port for promoting tissue in-growth around the percutaneous port. In one aspect, the percutaneous port includes a tubular structure having an outer surface, and a coil having an outer surface and comprised of a plurality of loops. Furthermore, at least a portion of the outer surface of the coil is joined to the outer surface of the tubular structure.

Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.

Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.

Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.

Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.

Abstract: Methods of using unidirectionally propagating action potentials (UPAPs) for vagus nerve stimulation and for certain disorders are provided. Stimulators capable of creating such UPAPs include, but are not limited to, miniature implantable stimulators (i.e., microstimulators), possibly with programmably configurable electrodes.

Abstract: An implantable microstimulator can include a housing with a surface containing a metal region. The housing defines an exterior and an interior. At least one conductive electrode is disposed on the exterior of the housing over the metal region of the housing. Adhesive is disposed between the metal region of the housing and the conductive electrodes. An electronic subassembly is disposed in the interior of the housing and coupled to the conductive electrodes through the housing.

Abstract: An implantable stimulator includes a tube assembly that is configured to house a number of components that are configured to apply at least one stimulus to at least one stimulation site within a patient. The tube assembly has a shape that allows the stimulator to be implanted within said patient in a pre-determined orientation. Exemplary methods of stimulating a stimulation site within a patient include applying an electrical stimulation current to a stimulation site via one or more electrodes extending along one or more sides of a stimulator. The stimulator has a shape allowing the stimulator to be implanted within the patient in a pre-determined orientation.

Abstract: Compact electronic modules, which may be used with implantable microstimulators and other medical and non-medical devices, and manufacture/assembly of such modules are described. Component and circuitry designs utilize unique redistribution techniques and attachment methods. A number of component designs and packaging configurations maximize the volume efficiency of electronic modules. Also included are improved processes and systems enabling the manufacture and assembly of such compact packages.

Abstract: Systems for providing stimulation with an implantable system control unit and for optimally positioning that system control unit include a system control unit configured to provide a stimulus to a patient with a member attached to the system control unit for pulling the system control unit into position within the patient. Methods of optimally positioning the implantable system control unit within a patient such that the system control unit is proximal to target tissue that is to be stimulated by the system control unit include threading a member through a patient's body using a needle, the member passing proximal to the target tissue and being attached to the system control unit, and pulling the system control unit into place with the member.

Abstract: Methods of using unidirectionally propagating action potentials (UPAPs) for cavernous nerve stimulation and for certain disorders are provided. Stimulators capable of creating such UPAPs include, but are not limited to, miniature implantable stimulators (i.e., microstimulators), possibly with programmably configurable electrodes.

Abstract: An implantable microstimulator includes a housing, an electronic subassembly, conductive vias, and an electrode arrangement. The housing defines an interior and an exterior with the electronic subassembly disposed in the interior of the housing. The conductive vias extend from the interior to the exterior of the housing. The electrode arrangement is disposed on the housing and includes a film substrate with electrodes disposed on the film substrate and coupled to the electronic subassembly through the plurality of vias.

Abstract: An implantable microstimulator can include a housing having a first end; an electronic subassembly disposed within the housing; a plurality of electrodes disposed on the housing and coupled to the electronic subassembly; and a dissecting tip disposed at the first end of the housing. Another implantable microstimulator includes a housing having a first end; an electronic subassembly disposed within the housing; a plurality of electrodes disposed on the housing and coupled to the electronic subassembly; and a extraction aid disposed at the first end of the housing and configured and arranged for attachment of an extraction line.